MedTrace Logo

Safety Tolerability and Pharmacokinetics of ALD403

NCT01579383 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2013-04-26

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALD403, a monoclonal antibody, administered by intravenous infusion and subcutaneous injection.

Conditions

  • Migraine Disorders

Interventions

BIOLOGICAL

ALD403

Single Dose IV infusion on Day 1

BIOLOGICAL

ALD403

Single Dose subcutaneous injection on Day 1

BIOLOGICAL

Sumatriptan

Single Dose subcutaneous injection on Day 1

Sponsors & Collaborators

  • Alder Biopharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Peter Hodsman, MD · Nucleus Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2012-12-31
Completion
2013-04-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01579383 on ClinicalTrials.gov